丁苯酞联合抗血小板药物治疗高龄老年脑梗死的疗效观察
| 作者: |
1孔德强,
1魏向东,
1王建桥,
2李战永
1 廊坊市人民医院神经内科，河北 廊坊 065000 2 廊坊师范学院生命科学学院，河北 廊坊 065000 |
| 通讯: |
李战永
Email: lizy1537@126.com |
| DOI: | 10.3978/j.issn.2095-6959.2016.04.002 |
| 基金: | 河北省廊坊市科学技术研究与发展计划项目, 2012013085 |
摘要
目的：观察丁苯酞联合阿司匹林、氯吡格雷治疗高龄老年脑梗死的疗效。方法：收集我院神经内科2012年1月至2015年6月入院治疗的高龄老年(≥80岁)脑梗死病例221例，按治疗方法分为4组：单抗组、双抗组、丁苯酞+单抗组、丁苯酞+双抗组。分别观察各组患者治疗4周前后的神经功能缺损评分(NIHSS评分)和血浆C反应蛋白(plasma C-reactive protein，CRP)水平的变化，对比4组间的NIHSS评分差值、CRP差值和临床治疗总有效率。结果：各组治疗前后NIHSS评分和血浆CRP水平均有显著差异(P<0.05)，各组NIHSS评分差值及血浆CRP水平差值变化趋势一致：丁苯酞+双抗组与其它3组均有显著差异(P<0.05)，丁苯酞+单抗组与双抗组之间无显著差别(P>0.05)。各组临床治疗总有效率比较：丁苯酞+双抗组治疗效果显著优于其它3组(P<0.05)，丁苯酞+单抗组总有效率显著高于单抗组(P<0.05)，丁苯酞+单抗组和双抗组的临床总有效率无明显差别(P>0.05)。结论：丁苯酞能显著提高抗血小板药物治疗高龄老年脑梗死的临床疗效。
关键词：
丁苯酞
抗血小板
脑梗死
NIHSS评分
C反应蛋白
Efficacy of butylphthalide combined antiplatelet treatment on cerebral infarction in elderly
CorrespondingAuthor: LI Zhanyong Email: lizy1537@126.com
DOI: 10.3978/j.issn.2095-6959.2016.04.002
Abstract
Objective: To investigate the effect of butylphthalide in combination with aspirin and/or clopidogrel in treating cerebral infarction of elderly. Methods: The clinical data of 221 cerebral infarction patients (≥80 years old) who underwent both antiplatelet drug therapies systematically and butylphthalide combined antiplatelet treatment in our hospital from Jan 2012 to Jun 2015 were reviewed. All cases were divided into 4 groups: aspirin group, aspirin and clopidogrel group, butylphthalide combined aspirin group, butylphthalide combined aspirin and clopidogrel group. The National Institute of Health stroke scale (NIHSS) score, plasma C-reactive protein (CRP) level and clinical efficacy after 4 weeks therapy of each group was analyzed respectively. Results: By systematic medication therapy, both NIHSS score and CRP level of each group were improved significantly (P<0.05), and the changes from pre- to post-treatment of above-mentioned parameters in each group showed consistent. Ebutylphthalide combined aspirin and clopidogrel group was more effective when compared to the other 3 groups in NIHSS score or CRP level (P<0.05). However, there was no remarkable difference between butylphthalide combined aspirin group and aspirin and clopidogrel group in respect of NIHSS score and CRP level (P>0.05). Additionally, the clinical efficacy in butylphthalide combined aspirin and clopidogrel group was better than other groups significantly (P<0.05), better clinical efficacy in butylphthalide combined aspirin group than aspirin group significantly (P<0.05), whereas no difference existed between aspirin and clopidogrel group and butylphthalide combined aspirin group about clinical efficacy (P>0.05). Conclusion: Butylphthalide can significantly improve antiplatelet therapy in elderly cerebral infarction.